Priority Date: 16.02.12 (US 201261599821P)

MODULATION OF FACTOR Xa INHIBITOR MEDIATED BLOOD LOSS BY PARTIAL AND TRANSIENT ADMINISTRATION OF ANTIDOTE

  • Application ID: EP13709603
  • Status: EXAMINATION IN PROGRESS

Applicant

Technology company logo small
Technology Company

Attorney

no operation time available
1300.65
Headquarter in London and 4 offices
active in Legal Services, IP Consulting, and IP Portfolio Processing

Specialization

This EP application has the IPC combination A61 (MEDICAL OR VETERINARY SCIENCE; HYGIENE) and C07 (ORGANIC CHEMISTRY). J A Kemp is specialized in the combination A61 and C07. We found, that TransMIT GmbH, Kailuweit & Uhlemann, Lederer Keller Patentanwälte Partnerschaft mbB, Vossius & Partner Patentanwälte Rechtsanwälte mbB, df-mp Dörries Frank-Molnia & Pohlman, Patentanwälte Rechtsanwälte PartG mbB and 221 others are specialized in all of these IPC classes as well. For a similar patent, they might be a good choice.

Timeline

  • 16.02.2012 - Priority Date (US 201261599821P)
  • 22.08.2013 - Publication A1 (WO2013123248)
  • 24.12.2014 - Publication A1 (EP2814503)

IPC Classification